Generic drug of the therapeutic class: Gastro-Entero-Hepatology
active ingredients: Pantoprazole
laboratory: Nycomed Gmbh
Enteric coated tablet
Box of 7
PANTOPRAZOL Control is indicated for the short-term treatment of symptoms of gastroesophageal reflux (eg, heartburn, acid regurgitation) in adults.
Dosage PANTOZOL CONTROL 20 mg Enteric coated tablet Box of 7
The recommended dose is 20 mg pantoprazole (one tablet) daily.
Taking tablets for 2 or 3 consecutive days may be necessary for symptom improvement. Once the symptoms are gone, treatment should be stopped. The duration of treatment should not exceed 4 weeks without medical advice.
If symptoms persist after 2 weeks of continuous treatment, the patient should consult a doctor.
No adjustment of the dose is necessary in the elderly or the hepatic or renal insufficiency.
PANTOZOL Control is not recommended for use in children and adolescents under 18 years of age due to insufficient data on efficacy and safety.
PANTOZOL Control 20 mg gastro-resistant tablet should not be crushed or crushed. It must be swallowed whole with a little water before a meal.
Hypersensitivity to the active substance or to any of the excipients (see section Composition ).
Should not be administered with atazanavir (see section 4.5. Interactions with other medicinal products and other forms of interaction ).
Pantozol Control side effects
About 5% of patients are likely to have side effects. The most commonly reported adverse events are diarrhea and headache in approximately 1% of patients. The following side effects have been reported with pantoprazole.
The adverse reactions listed in the table below are classified according to the order of frequency defined by the MedDRA classification:
Very common (≥ 1/10), common (≥1 / 100, <1/10), infrequent (≥ 1/1000, <1/100), rare (≥ 1/10 000, <1 / 1, 000), very rare (<1 / 10, 000), not known (can not be estimated based on available data).
Within each frequency group, adverse effects are presented in descending order of severity.
Table 1. Adverse effects of pantoprazole reported in post-marketing clinical trials
Not known frequency
Blood and lymphatic system disorders
Nervous system disorders
Visual disorders / blurred vision
Diarrhea; nausea / vomiting; abdominal distension and meteorism; constipation; dry mouth; abdominal pain and discomfort
Renal and urinary disorders
Skin and subcutaneous tissue disorders
Skin rash / rash / eruption; pruritus
Hives; Quincke's edema
Stevens-Johnson Syndrome; Lyell syndrome; erythema multiforme; photosensitivity
Musculoskeletal and systemic disorders
Metabolism and nutrition disorders
Hyperlipidemia and lipid increase
(triglycerides, cholesterol); change in weight
General disorders and administration site conditions
Asthenia, fatigue and discomfort
Increase in body temperature; peripheral edema
Hypersensitivity (including anaphylactic reaction and anaphylactic shock)
Increased liver enzymes (transaminases, γ-GT)
hepatocellular; jaundice; hepatocellular insufficiency
Depression (and other aggravations)
Disorientation (and other aggravations)
Hallucinations; confusion (especially in predisposed patients); aggravation of these disorders in case of pre-existence
Reproductive organs and breast disease